18F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies

…, KM Jones, RA Werner, RA Salas-Fragomeni… - Annals of nuclear …, 2019 - Springer
Purpose This meta-analysis aims to establish the diagnostic performance of 18 F-NaF-PET/CT
for the detection of bone metastases in prostate cancer patients. The performance of 18 F-…

Imaging of nonprostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms

RAS Fragomeni, T Amir, S Sheikhbahaei… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is
highly overexpressed on prostate cancer epithelial cells and for which there is a growing …

CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma

RA Salas Fragomeni, HW Chung, Y Landesman… - Molecular cancer …, 2013 - AACR
Resistance to BRAF inhibitor therapy places priority on developing BRAF inhibitor-based
combinations that will overcome de novo resistance and prevent the emergence of acquired …

[HTML][HTML] Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics

DT Frederick, RA Salas Fragomeni, A Schalck… - PloS one, 2014 - journals.plos.org
While response rates to BRAF inhibitiors (BRAFi) are high, disease progression emerges
quickly. One strategy to delay the onset of resistance is to target anti-apoptotic proteins such as …

Prostate-specific membrane antigen–targeted imaging with [18F] DCFPyL in high-grade gliomas

RAS Fragomeni, JR Menke, M Holdhoff… - Clinical nuclear …, 2017 - journals.lww.com
High-grade gliomas (World Health Organization grade III–IV) are highly lethal primary brain
tumors. Imaging modalities, including MRI and FDG PET, provide a limited ability to …

Uptake of prostate-specific membrane antigen–targeted 18F-DCFPyL in cerebral radionecrosis: implications for diagnostic imaging of high-grade gliomas

RAS Fragomeni, KJ Pienta, MG Pomper… - Clinical nuclear …, 2018 - journals.lww.com
Recent PET imaging of glioblastoma multiforme and other high-grade gliomas using
prostate-specific membrane antigen (PSMA)–targeted small-molecule radiotracers suggests a role …

Clinical experience with 18F-labeled small molecule inhibitors of prostate-specific membrane antigen

SP Rowe, MA Gorin, RAS Fragomeni, A Drzezga… - PET clinics, 2017 - pet.theclinics.com
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is
currently being extensively investigated as a target for prostate cancer (PCa) molecular …

Perceptions of adequacy of breast imaging training in the United States among breast radiologists

RAS Fragomeni, EB Ambinder, K Myers… - Journal of Breast …, 2021 - academic.oup.com
Objective To evaluate the perceptions of breast imaging training in the United States among
practicing breast radiologists. Methods An anonymous electronic survey was sent to …

Pulmonary perfusion changes following extracardiac lateral fontan and bilateral bidirectional glenn shunt in hypoplastic right ventricle with duplicated superior vena …

RAS Fragomeni, EB Turkbey, BC Jones… - Clinical Nuclear …, 2017 - journals.lww.com
The incidence of congenital heart disease requiring specialized care is 2.5 to 3 per 1000
live births with a prevalence of congenital heart disease of 81.4 per 10,000 live births. Total …

Effect of inhibition of nuclear protein export using a novel CRM1 inhibitor on the apoptotic response to SN38 in preclinical colon cancer models.

HW Chung, RA Salas Fragomeni… - Journal of Clinical …, 2012 - ascopubs.org
609 Background: Resistance to conventional chemotherapy remains a major challenge in
Stage IV colon cancer. CRM1 inhibition leads to nuclear sequestration of proteins such as …